NO20055172L - Terapeutiske kombinasjoner av atymiske antipsykotiske midler med gabamodulatorer og/eller antionvulsant medikamenter - Google Patents

Terapeutiske kombinasjoner av atymiske antipsykotiske midler med gabamodulatorer og/eller antionvulsant medikamenter

Info

Publication number
NO20055172L
NO20055172L NO20055172A NO20055172A NO20055172L NO 20055172 L NO20055172 L NO 20055172L NO 20055172 A NO20055172 A NO 20055172A NO 20055172 A NO20055172 A NO 20055172A NO 20055172 L NO20055172 L NO 20055172L
Authority
NO
Norway
Prior art keywords
combinations
gabam
athymic
modulators
disorders
Prior art date
Application number
NO20055172A
Other languages
English (en)
Norwegian (no)
Other versions
NO20055172D0 (no
Inventor
Steven Joseph Romano
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33452430&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20055172(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of NO20055172D0 publication Critical patent/NO20055172D0/no
Publication of NO20055172L publication Critical patent/NO20055172L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20055172A 2003-05-16 2005-11-03 Terapeutiske kombinasjoner av atymiske antipsykotiske midler med gabamodulatorer og/eller antionvulsant medikamenter NO20055172L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US47118803P 2003-05-16 2003-05-16
PCT/IB2004/001517 WO2004100992A2 (fr) 2003-05-16 2004-05-03 Combinaisons therapeutiques d'antipsychotiques atypiques avec des modulateurs de l'acide 4-aminobutanoique et/ou des medicaments anticonvulsivants

Publications (2)

Publication Number Publication Date
NO20055172D0 NO20055172D0 (no) 2005-11-03
NO20055172L true NO20055172L (no) 2005-12-13

Family

ID=33452430

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20055172A NO20055172L (no) 2003-05-16 2005-11-03 Terapeutiske kombinasjoner av atymiske antipsykotiske midler med gabamodulatorer og/eller antionvulsant medikamenter

Country Status (16)

Country Link
US (1) US20050004106A1 (fr)
EP (1) EP1633400A2 (fr)
JP (1) JP2006528676A (fr)
KR (1) KR20060011873A (fr)
CN (1) CN1791430A (fr)
AU (1) AU2004237951A1 (fr)
BR (1) BRPI0410271A (fr)
CA (1) CA2525366A1 (fr)
CL (1) CL2004001046A1 (fr)
CO (1) CO5700793A2 (fr)
MX (1) MXPA05012317A (fr)
NO (1) NO20055172L (fr)
RU (1) RU2005135454A (fr)
TW (2) TW200509932A (fr)
WO (1) WO2004100992A2 (fr)
ZA (1) ZA200509252B (fr)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100491282B1 (ko) 1996-07-24 2005-05-24 워너-램버트 캄파니 엘엘씨 통증 치료용 이소부틸가바 및 그의 유도체
US20050215552A1 (en) * 2002-05-17 2005-09-29 Gadde Kishore M Method for treating obesity
RU2350327C2 (ru) 2003-04-29 2009-03-27 Ориксиджен Серапьютикс, Инкорпорэйтд Составы, вызывающие потерю веса
US9125939B2 (en) * 2003-05-23 2015-09-08 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and mood stabilizers for treating mood disorders
MXPA06002455A (es) * 2003-09-02 2006-08-31 Pfizer Prod Inc Formas de dosificacion de liberacion sostenida de ziprasidona.
US7429580B2 (en) * 2004-01-13 2008-09-30 Orexigen Therapeutics, Inc. Compositions of an anticonvulsant and an antipsychotic drug and methods of using the same for affecting weight loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
JP2007519705A (ja) * 2004-01-29 2007-07-19 ファイザー・プロダクツ・インク Ｃｎｓ障害を治療するための非定型抗精神病薬とアミノメチルピリジルオキシメチル／ベンゾイソオキサゾールアザビシクロ誘導体の組合せ
US20050171088A1 (en) * 2004-01-30 2005-08-04 Astrazeneca Ab Treatment of psychoses with dibenzothiazepine antipsychotic
GB0405200D0 (en) * 2004-03-08 2004-04-21 Pfizer Ltd Combinations comprising alpha-2-delta ligands
BRPI0510593A (pt) * 2004-05-03 2007-11-20 Univ Duke composições para afetar a perda de peso
JP2008534522A (ja) 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
LT2982372T (lt) * 2005-04-05 2020-10-26 Yale University Glutamatą moduliuojantys agentai psichikos sutrikimų gydymui
US20080305161A1 (en) * 2005-04-13 2008-12-11 Pfizer Inc Injectable depot formulations and methods for providing sustained release of nanoparticle compositions
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
AU2006252708A1 (en) * 2005-05-31 2006-12-07 Orexigen Therapeutics, Inc. Methods and compositions for managing psychotic disorders
US20080058282A1 (en) 2005-08-30 2008-03-06 Fallon Joan M Use of lactulose in the treatment of autism
EP1948238B1 (fr) * 2005-11-10 2013-08-28 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Compositions et procédés pour le traitement de l'addiction et d'autres troubles neuropsychiatriques
EP1951212A2 (fr) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions et procedes d augmentation de la sensibilite a l insuline
AR057946A1 (es) * 2005-11-28 2007-12-26 Orexigen Therapeutics Inc Formulacion de zonisamida de liberacion sostenidda
WO2007096489A1 (fr) * 2006-02-17 2007-08-30 Trimaran Limited Nouvelles compositions pharmaceutiques destinees a optimiser des traitements de substitution et elargir la pharmacopee au traitement global des addictions
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
TW201811315A (zh) 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
CA2668885C (fr) * 2006-11-09 2016-08-02 Orexigen Therapeutics, Inc. Procedes d'administration de medications pour la perte de poids
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
MX2007008323A (es) * 2007-07-06 2009-02-18 World Trade Imp Export Wtie Ag Composicion farmaceutica que comprende la combinacion de un agente derivado benzisoxazolico y un agente benzodiazepinico.
US8658163B2 (en) 2008-03-13 2014-02-25 Curemark Llc Compositions and use thereof for treating symptoms of preeclampsia
EP2303025A4 (fr) 2008-05-30 2012-07-04 Orexigen Therapeutics Inc Procédés pour traiter des pathologies des graisses viscérales
US9320780B2 (en) 2008-06-26 2016-04-26 Curemark Llc Methods and compositions for the treatment of symptoms of Williams Syndrome
EP2318035B1 (fr) 2008-07-01 2019-06-12 Curemark, Llc Procédés et compositions pour le traitement de symptômes de troubles de santé neurologiques et mentaux
US10776453B2 (en) 2008-08-04 2020-09-15 Galenagen, Llc Systems and methods employing remote data gathering and monitoring for diagnosing, staging, and treatment of Parkinsons disease, movement and neurological disorders, and chronic pain
US20100092447A1 (en) 2008-10-03 2010-04-15 Fallon Joan M Methods and compositions for the treatment of symptoms of prion diseases
US9084784B2 (en) 2009-01-06 2015-07-21 Curelon Llc Compositions and methods for the treatment or the prevention of E. coli infections and for the eradication or reduction of E. coli surfaces
ES2668909T3 (es) 2009-01-06 2018-05-23 Galenagen, Llc Composiciones que comprenden proteasa, amilasa y lipasa para su uso en el tratamiento de infecciones por Staphylococcus aureus
US9056050B2 (en) 2009-04-13 2015-06-16 Curemark Llc Enzyme delivery systems and methods of preparation and use
US9511125B2 (en) 2009-10-21 2016-12-06 Curemark Llc Methods and compositions for the treatment of influenza
EP3659604A1 (fr) 2010-01-11 2020-06-03 Nalpropion Pharmaceuticals, Inc. Méthodes d'amaigrissementu pour des patients souffrant d'une dépression sévère
GB201004603D0 (en) 2010-03-19 2010-05-05 2Td Ltd Drill bit
CA2802733C (fr) 2010-06-24 2017-11-21 Alkermes Pharma Ireland Limited Promedicaments de composes nh-acides : derives esters, carbonates, carbamates et phosphonates
RU2485946C2 (ru) * 2011-04-13 2013-06-27 Государственное образовательное учреждение высшего профессионального образования "Ростовский государственный медицинский университет" Министерства здравоохранения и социального развития Российской Федерации Способ выбора психофармакотерапии панического расстройства
CN106310242B (zh) * 2011-04-21 2020-02-28 柯尔马克有限责任公司 用于治疗神经精神障碍的化合物
US10350278B2 (en) 2012-05-30 2019-07-16 Curemark, Llc Methods of treating Celiac disease
PT3730132T (pt) 2012-06-06 2022-08-16 Nalpropion Pharmaceuticals Llc Composição para utilização num método de tratamento de excesso de peso e obesidade em doentes com alto risco cardiovascular
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物
US8992951B2 (en) 2013-01-09 2015-03-31 Sapna Life Sciences Corporation Formulations, procedures, methods and combinations thereof for reducing or preventing the development, or the risk of development, of neuropathology as a result of trauma
CN103505734A (zh) * 2013-10-08 2014-01-15 湖南工业大学 包含r-氨基丁酸和抗癫痫药物的组合
US8969371B1 (en) 2013-12-06 2015-03-03 Orexigen Therapeutics, Inc. Compositions and methods for weight loss in at risk patient populations
CA3047354A1 (fr) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Systeme therapeutique transdermique contenant de l'asenapine et un polysiloxane ou un polyisobutylene
RU2762896C2 (ru) 2016-12-20 2021-12-23 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин
WO2018191233A1 (fr) 2017-04-10 2018-10-18 Curemark, Llc Compositions pour le traitement de l'accoutumance
EP3644973B1 (fr) 2017-06-26 2021-03-24 LTS LOHMANN Therapie-Systeme AG Système thérapeutique transdermique contenant de l'asénapine et polymère hybride acrylique silicone
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
AU2019205329B2 (en) * 2018-01-05 2023-04-20 Impel Pharmaceuticals Inc. Intranasal delivery of olanzapine by precision olfactory device
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN110958876B (zh) 2018-06-20 2020-12-18 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
CN114945396B (zh) * 2019-11-13 2024-07-02 詹森生物科技公司 药物递送装置感测模块
US11541009B2 (en) 2020-09-10 2023-01-03 Curemark, Llc Methods of prophylaxis of coronavirus infection and treatment of coronaviruses
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2948718A (en) 1960-08-09 New n-heterocyclic compounds
US2409754A (en) * 1946-10-22 Method for obtaining hydantoins
US2409654A (en) 1941-10-30 1946-10-22 Air Reduction Billet scarfing method and apparatus
CH449645A (de) * 1963-07-09 1968-01-15 Ciba Geigy Verfahren zur Herstellung neuer Aminosäuren
CH427803A (de) * 1963-12-06 1967-01-15 Geigy Ag J R Verfahren zur Herstellung eines neuen Isoxazolderivates
US3539573A (en) * 1967-03-22 1970-11-10 Jean Schmutz 11-basic substituted dibenzodiazepines and dibenzothiazepines
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US3960927A (en) * 1975-03-18 1976-06-01 Richardson-Merrell Inc. Olefinic derivatives of amino acids
FR2319338A1 (fr) * 1975-08-01 1977-02-25 Synthelabo Nouveaux derives de a- phenyl benzylideniques des acides amines, leur preparation et les medicaments qui en contiennent
NL7605526A (nl) * 1976-05-24 1977-11-28 Akzo Nv Nieuwe tetracyclische derivaten.
FR2415099A1 (fr) * 1978-01-20 1979-08-17 Ile De France Nouveaux derives de 4-amino-5-alkylsulfonyl ortho-anisamides, leurs procedes de preparation et leur application comme psychotropes
AR227521A1 (es) * 1979-06-01 1982-11-15 Wellcome Found Procedimiento para la preparacion de derivados de 3,5-diamino-6-(fenil substituido)-1,2,4-triazinas e intermediario para realizar el procedimiento
FR2492258A1 (fr) * 1980-10-17 1982-04-23 Pharmindustrie Nouveau medicament a base d'amino-2 trifluoromethoxy-6 benzothiazole
LU83729A1 (fr) 1981-11-04 1983-09-01 Galephar Sels d'acide valproique,leur preparation et leur utilisation
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
IE58370B1 (en) * 1985-04-10 1993-09-08 Lundbeck & Co As H Indole derivatives
DK288385D0 (da) * 1985-06-26 1985-06-26 Novo Industri As Aminosyrederivater
GB8607684D0 (en) * 1986-03-27 1986-04-30 Ici America Inc Thiazepine compounds
US4883795A (en) * 1988-01-22 1989-11-28 Pfizer Inc. Piperazinyl-heterocyclic compounds
US4831031A (en) 1988-01-22 1989-05-16 Pfizer Inc. Aryl piperazinyl-(C2 or C4) alkylene heterocyclic compounds having neuroleptic activity
US5006528A (en) * 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US5238945A (en) * 1989-04-11 1993-08-24 H. Lundbeck A/S Method of treating psychoses
GB8908085D0 (en) * 1989-04-11 1989-05-24 Lundbeck & Co As H New therapeutic use
US5229382A (en) 1990-04-25 1993-07-20 Lilly Industries Limited 2-methyl-thieno-benzodiazepine
US6197819B1 (en) * 1990-11-27 2001-03-06 Northwestern University Gamma amino butyric acid analogs and optical isomers
US5312925A (en) 1992-09-01 1994-05-17 Pfizer Inc. Monohydrate of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2H-indol-2-one-hydrochloride
FI106505B (fi) * 1993-09-27 2001-02-15 Nokia Networks Oy Langattoman tilaajaliittymän toteuttava radiojärjestelmä sekä tilaajalaite radiojärjestelmää varten
CN1079670C (zh) * 1994-03-02 2002-02-27 阿克佐诺贝尔公司 舌下或颊给药的药物组合物
FI100077B (fi) * 1995-01-04 1997-09-15 Nokia Telecommunications Oy Johdottoman tilaajaliitännän toteuttava radiojärjestelmä
TW491847B (en) 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
IL125951A (en) 1997-09-05 2003-09-17 Pfizer Prod Inc A pharmaceutical composition comprising a piperazinyl-heterocyclic compound for treating tourette's syndrome, obsessive compulsive disorder, chronic motor or vocal tic disorder in a mammal
IL127497A (en) 1997-12-18 2002-07-25 Pfizer Prod Inc Medicinal products containing piperazinyl-heterocyclic compounds for the treatment of psychiatric disorders
US6387904B2 (en) 1998-05-18 2002-05-14 Pfizer Inc Method of treating glaucoma and ischemic retinopathy
US6420369B1 (en) * 1999-05-24 2002-07-16 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating dementia
US6706892B1 (en) * 1999-09-07 2004-03-16 Conjuchem, Inc. Pulmonary delivery for bioconjugation
US6599532B2 (en) * 2000-01-13 2003-07-29 Osmotica Corp. Osmotic device containing alprazolam and an antipsychotic agent
JP2004527553A (ja) * 2001-04-26 2004-09-09 オーソ−マクニール・フアーマシユーチカル・インコーポレーテツド 抗痙攣性誘導体と非典型的抗精神病薬を用いた共治療を含んで成る精神病性障害治療

Also Published As

Publication number Publication date
KR20060011873A (ko) 2006-02-03
US20050004106A1 (en) 2005-01-06
WO2004100992A3 (fr) 2005-01-20
TW200509932A (en) 2005-03-16
CL2004001046A1 (es) 2005-03-28
CN1791430A (zh) 2006-06-21
WO2004100992A2 (fr) 2004-11-25
NO20055172D0 (no) 2005-11-03
AU2004237951A1 (en) 2004-11-25
TW200735873A (en) 2007-10-01
BRPI0410271A (pt) 2006-05-16
RU2005135454A (ru) 2006-06-27
ZA200509252B (en) 2007-09-26
MXPA05012317A (es) 2006-01-30
CA2525366A1 (fr) 2004-11-25
JP2006528676A (ja) 2006-12-21
CO5700793A2 (es) 2006-11-30
EP1633400A2 (fr) 2006-03-15

Similar Documents

Publication Publication Date Title
NO20055172L (no) Terapeutiske kombinasjoner av atymiske antipsykotiske midler med gabamodulatorer og/eller antionvulsant medikamenter
Ballard et al. The role of dissociation in ketamine’s antidepressant effects
Moghaddam et al. From revolution to evolution: the glutamate hypothesis of schizophrenia and its implication for treatment
Berk et al. Stage managing bipolar disorder
Anderson et al. Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions
Baudry et al. Calpain-1 and calpain-2: the yin and yang of synaptic plasticity and neurodegeneration
EA200700333A1 (ru) Терапевтические применения ингибиторов rtp801
CY1112238T1 (el) Αναστολεις μιτωτικης κινεσινης και μεθοδοι χρησης αυτων
SG146653A1 (en) Methods and reagents for the treatment of immunoinflammatory disorders
WO2005063296A3 (fr) Combinaison therapeutique d'amelioration neuro-cognitive et de traitement de troubles psychotiques
WO2006105516A3 (fr) Compositions et procedes pour le diagnostic et le traitement de troubles neuropsychiatriques
EP1766077A4 (fr) Genes et voies exprimes de maniere differentielle dans des troubles bipolaires et/ou troubles depressifs majeurs
AR043188A1 (es) Metodos y composiciones para el tratamiento de enfermedades y trastornos asociados con niveles elevados de citoquinas proinflamatorias
EA201071245A1 (ru) Новые терапевтические подходы для лечения болезни альцгеймера и связанных нарушений посредством модулирования реакции клеток на стресс
MY149855A (en) Benzimidazole derivatives and their use for modulating the gaba? receptor complex
Rakesh et al. Beyond serotonin: newer antidepressants in the future
MXPA05012358A (es) Combinacion farmaceutica que comprende modafinilo y otra droga.
Lamprecht et al. The Wnt–NAD+ axis in cancer, aging, and tissue regeneration
DK1836665T3 (da) Fremgangsmåde til specialtilpasset afgivelse af medikamentkombinationsprodukter med variabel dosis til individualisering af terapier
BRPI0510639A (pt) composto ou um sal ou uma pró-droga farmaceuticamente aceitável do mesmo, composição farmacêutica, métodos de tratar ou prevenir distúrbios, de terapia de reposição hormonal, de abaixar nìveis de colesterol, triglicerìdeos ou ldl, de tratar cognição prejudicada ou prover neuroproteção, de prevenir concepção, de modular ou agonizar especificamente um ou mais receptores de estrogênio e, uso de um composto
WO2004047727A3 (fr) Compositions et procedes pour diagnostiquer et traiter des troubles de l'humeur
Kang et al. Decoding orofacial pain: a translational review of mechanisms and novel therapies
McLaughlin Serotonin and the Brain: Exploring the 5-HT System's Role in Depression
Vukadinovic Schizophrenia as a disturbance of cortical sensory maps
Kumari et al. Cognitive behaviour therapy for psychosis: insights from neuroimaging

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application